Lock-anti-4-1BB antibody - PrecisemAb
Alternative Names: Lock-4-1-BBLatest Information Update: 01 Sep 2022
Price :
$50 *
At a glance
- Originator PrecisemAb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lymphoma
Most Recent Events
- 03 Aug 2022 Lock-anti-4-1BB antibody - PrecisemAb is available for licensing as of 03 Aug 2022. https://www.precisemab.com.tw/Partners
- 03 Aug 2022 Preclinical trials in Lymphoma in Taiwan (Parenteral) (PrecisemAb pipeline, August 2022)
- 29 Jul 2022 PrecisemAb has patent protection for Universal Antibody Lock technology in USA and China